Creating a database for pediatric CNS tumors in Asia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to establish an Asian consortium focused on collecting data related to pediatric central nervous system (CNS) tumors, specifically CNS germinoma. The study will begin by registering patients diagnosed with CNS germinoma from 2022 to 2027 and will develop clinical protocols tailored for pediatric CNS tumors in Asia. The consortium will also analyze medical records until 2030 and conduct interim assessments to ensure data quality and integrity. The final analysis of treatment outcomes is projected for 2032.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A patient who was diagnosed with CNS GCT and agreed to participate in the research between 2022-2027.

  * Patients diagnosed between 2016-2022 can be enrolled if the participating institute has IRB approval for recruiting these patients as separate IRB document (Seoul Asan Hospital) or by comprehensive IRB document (Singapore NCC, Taiwan Medical University), or by recruitment on the basis of acquirement of the consent form for research (NCC, Korea).

    * The age at the time of diagnosis is 0\< ≤40 years

      * A patent who has been diagnosed with the relevant tumor via an operation or a biopsy ⑤ In the case of CNS germinoma, a biopsy may not have been performed on a patient. In this case, the patient may register as germinoma if he or she meets the following criteria: -Germinoma is strongly suspected radiologically, and a tumor marker from serum or cerebrospinal fluid (CSF) has not increased above the institute's reference normal value; -Germinoma is suspected radiologically, and a tumor marker from serum or CSF has elevated above the institute's reference normal value (tumor markers may be AFP or hCG)

Exclusion Criteria:

① The patient or the guardian of the patient did not consent to participate.

Where it's running

• National Cancer Center, Korea
  Goyang-si, Gyeonggi-do, South Korea Recruiting

Study contacts

• Principal investigator: Joo-young Kim, M.D., Ph.D. — National Cancer Center
• Study coordinator: Joo-young Kim, M.D., Ph.D.
• Email: jooyoungcasa@ncc.re.kr
• Phone: +82 31 920 1724

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• Home-based mobile neurological check for people with brain tumors

  This project will test whether people with brain tumors older than 5 can use the Iskhaa Android app to do guided self-neurological exams, upload short videos, and have an AI model detect changes that might predict neurological worsening.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT07236840

• Testing PHST001 for advanced solid tumors

  This study is testing a new treatment called PHST001 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 20 sites Phase 1 Pheast Therapeutics · Beverly Hills, California and 19 other locations · NCT06840886

• Entrectinib treatment for young children with specific CNS tumors

  This study is testing if a new treatment called entrectinib can help young children under 3 with certain brain tumors feel better and live longer.

  Recruiting at 6 sites Phase 2 St. Jude Children's Research Hospital · Memphis, Tennessee and 5 other locations · NCT06528691

• Using artificial intelligence to improve radiation treatment for brain tumors

  This study is testing whether using artificial intelligence can make radiation treatment for brain tumors more accurate and help doctors predict how well patients will respond to the treatment.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT06036394

• Using ONC206 to treat newly diagnosed and recurrent brain tumors in children and young adults

  This study is testing a new treatment called ONC206, alone or with radiation, to see if it can help children and young adults with newly diagnosed or recurring brain tumors feel better.

  Recruiting at 7 sites Phase 1 University of California, San Francisco · San Francisco, California and 6 other locations · NCT04732065

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.